Xcout Intel
Brenig Therapeutics, Inc.
Brenig Therapeutics, Inc. is a clinical-stage biotechnology and drug development company focused on advancing small-molecule therapies.
Subscribe to see Brenig Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Brenig Therapeutics, Inc. at a glance
Brenig Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $30M in July 2024. Xcout tracks 2 named people at Brenig Therapeutics, Inc., including Megan McGill (Chief Executive Officer).
Brenig Therapeutics, Inc. leadership
- Megan McGillChief Executive Officer
- Iain DukesChairman of the Board
Brenig Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $30M | — | |
| Series A | $65M | 5 named | |
| — | Undisclosed | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Brenig Therapeutics, Inc. competitors
A few of Brenig Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
BreStem Therapeutics, Inc. is a clinical-stage biotechnology company located in Raleigh, North Carolina, focused on developing novel therapeutics to fight various diseases.
Beren Therapeutics P.B.C. is a fully integrated biotechnology company headquartered in Thousand Oaks, California, that advances biology and chemistry to develop first-in-class therapeutics addressing the root causes of diseases.
Cadenza Bio, Inc. is a privately held preclinical biotechnology company founded in 2022 and headquartered in Oklahoma City, dedicated to developing novel, non-steroidal, highly selective small-molecule therapies.
Brenus Pharma is a pioneering clinical-stage biotech company headquartered in Clermont-Ferrand, France. The firm focuses on developing innovative immunotherapies aimed at preventing cancer recurrence and addressing solid tumors.
Sharp Therapeutics Corp. is a preclinical-stage biotechnology and drug discovery company that develops small molecule therapies to treat genetic diseases and hereditary disorders. The company combines high-speed experimentation and computational methods to advance its drug discovery platform.
BridGene Biosciences, Inc. is a biotechnology company headquartered in San Jose, California, pioneering next-generation chemoproteomics through its IMTAC platform. The company is focused on discovering and developing innovative small molecule drugs for high-value targets.
Get Brenig Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Brenig Therapeutics, Inc. in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access